drugset / Trial / NCT02181764

A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia

NCT02181764

Phase 1 Completed 15 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.

Timeline

Start
2014-07
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Burosumab Monoclonal antibody 0.3 mg/kg Subcutaneous
Subject Burosumab Monoclonal antibody 0.6 mg/kg Subcutaneous
Subject Burosumab Monoclonal antibody 1 mg/kg Subcutaneous